Mersana Therapeutics's revenue for the
three
months ended in Dec. 2023 was $10.70 Mil.
Its revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $36.86 Mil.
Mersana Therapeutics's Revenue per Share for the
three
months ended in Dec. 2023 was $0.09.
Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.32.
Warning Sign:
Mersana Therapeutics Inc revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Mersana Therapeutics was 11.60% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 190.00% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -20.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 9 years, Mersana Therapeutics's highest 3-Year average Revenue per Share Growth Rate was 190.00% per year. The lowest was -87.00% per year. And the median was -22.95% per year.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Mersana Therapeutics's Revenue
For the Biotechnology subindustry, Mersana Therapeutics's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mersana Therapeutics's Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Mersana Therapeutics's Revenue distribution charts can be found below:
* The bar in red indicates where Mersana Therapeutics's Revenue falls into.
Mersana Therapeutics Revenue Calculation
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $36.86 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Mersana Therapeutics Revenue Related Terms
Thank you for viewing the detailed overview of Mersana Therapeutics's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Mersana Therapeutics (Mersana Therapeutics) Business Description
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs include XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MRSN has been successfully added to your 